ORG
IRA Medicare Drug Price Negotiation: Round Three Expected in 2028 with Reforms Aimed at Pharma Manageability
IRA negotiations; Medicare drug prices; Round three; pharma impact; pill penalty; Executive Order 14273
Eikon and Veradermics Announce IPO Targets Amid Biotech Market Optimism
Eikon Therapeutics; Veradermics; IPO; biotech; hair loss; cancer drugs; Nasdaq; NYSE
Formation Bio Eyes Abivax-Like Success with Chinese Drug Licensing Deal Targeting Same Mechanism
Formation Bio; Abivax; licensing deal; China; cancer drug; PD-1/VEGF; biotech
HHS Issues Guidance to Shield Pharma from Anti-Kickback Violations in TrumpRx Direct-to-Consumer Drug Sales
TrumpRx; HHS; anti-kickback statute; direct-to-consumer; prescription drugs; OIG bulletin
Seno Medical’s Next-Generation Imagio Imaging System Receives EU MDR CE Mark Certification
Seno Medical; Imagio Imaging System; EU MDR CE Mark; opto-acoustic imaging; breast cancer diagnostics; Model 9100
Unravel Biosciences and The SCN2A Foundation Announce Drug Discovery Collaboration
Unravel Biosciences; SCN2A Foundation; drug discovery; SCN2A mutations; autism; epilepsy; loss-of-function; AI therapeutics
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences; Samit Hirawat; Board of Directors; appointment; non-opioid pain therapies
FDA Places Clinical Holds on Regenxbio’s RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient
FDA clinical hold; Regenxbio; RGX-111; RGX-121; brain tumor; gene therapy; MPS I; MPS II; AAV vector
FDA Lifts Clinical Hold on Intellia’s MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN
FDA; Intellia Therapeutics; clinical hold; MAGNITUDE-2; nex-z; ATTRv-PN; gene editing; CRISPR
Biopharma Sentiment Index Q1 2026: Positive Outlook Amid Rally and Challenges
biopharma sentiment; biotech rally; 2026 outlook; Deutsche Bank; RBC Capital; M&A activity; FDA uncertainty